Posts in LSE:ANCR

Animalcare completes acquisition of Ecuphar

Animalcare has completed its acquisition of Ecuphar NV and a placing of 9,340,168 shares at 350p to raise approximately £32.7m, gross.

The placing consisted of 8,571,428 new shares by the company and the sale of 768,740 shares sold by the selling shareholders at the placing price.

At 8:09am: (LON:ANCR) Animalcare Group PLC share price was +2.5p at 357.5p

Animalcare shareholders approve acquisition and placing

Animalcare Group has confirmed that, at the General Meeting held today, all resolutions in connection with the the proposed share placing and the acquisition of Ecuphar NV were passed.

The acquisition and placing are expected to complete tomorrow.

In aggregate, 38,691,790 New Ordinary Shares have been allotted and issued pursuant to the Proposals, comprising 8,571,428 New Placing Shares, 1,368,896 Option Shares and 28,751,466 Consideration Shares.

At 1:22pm: (LON:ANCR) Animalcare Group PLC share price was +2.5p at 357.5p

Top ranked shares for the future

Top ranked shares for the future

After upgrading his decision engine, companies analyst Richard Beddard thinks he's got to the heart of investing and the reasons we so often make mistakes.

A high-flying small-cap worth buying?

A high-flying small-cap worth buying?

This AIM company has just completed a complicated deal, but don't worry, companies analyst Richard Beddard has managed to make sense of it all.

Animalcare resumes trading on AIM

Trading in Animalcare's shares has resumed on AIM following the publication of an admission document for the proposed acquisition of Ecuphar.

At 9:56am: (LON:ANCR) Animalcare Group PLC share price was -20p at 372.5p

Animalcare to acquire Ecuphar

Animalcare Group has agreed to acquire Ecuphar NV, a European animal health company focused on the development and sale of veterinary pharmaceutical products.

The acquisition constitutes a reverse takeover under AIM Rules and is conditional upon shareholder approval.

Animalcare said the consideration for the acquisition was structured on a consolidated Animalcare/Ecuphar enlarged issued share capital ratio of 37:63 (after taking into account dilution from certain Animalcare incentive arrangements).

It said this would be satisfied through the issue of consideration shares and cash to the Ecu

10 top AIM stocks for ISA season

10 top AIM stocks for ISA season

Despite thrashing blue-chips in the past year, there are still some great small-caps worth buying. Stockopedia's Ben Hobson names the very best quality and momentum stocks on AIM right now.

2 micro-cap stocks I’ve added to my watch list

The small-cap effect is one of the best known phenomenons in investing. Simply put, smaller companies have been shown to generate substantially better returns than larger companies over the long term thanks to their ability to grow earnings and profits at a rapid pace. Combine this with the beauty of compounding and it's quite possible for dedicated investors to turn an initially modest amount of money into a small fortune. Better still, this tendency is even more pronounced the further down the market spectrum you go.

3 growth stocks that could make you rich

Today I'm looking at three companies with strong momentum and the financial performance to back it up. Will these growth stocks continue to climb, as we head into March?

Small cap, big growth

Veterinary medicine supplier Animalcare Group (LSE:ANCR) may not be a company that's on your radar. But the group's shares have risen by 56% over the last 12 months and recent results suggest that the shares may be worth a closer look.

Animalcare underlying profits rise

Animalcare Group posted first half underlying operating profits of £1.9m, 22.6% up on last time.

Revenues for the six months to the end of December were up 12% at £7.97m and underlying EBITDA rose by 26% to £2.12m.

The interim dividend of 2p per share was 11.1% higher.

Chairman James Lambert said: "The business continued to perform strongly during the first six months of its financial year with sales up by 12% to £8m."

He said that given the strong start to the current financial year, and the expected launch of more new pharmaceutical products in the second half, th